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Abstract 
Objectives: To evaluate rotavirus vaccination in Malaysia from the household’s perspective. The ECEA 
framework quantifies the broader value of universal vaccination starting with non-health benefits such 
as financial risk protection and equity. These dimensions better enable decision-makers to evaluate poli-
cy on the public finance of health programs. 
Methods: We use an extended cost-effectiveness analysis (ECEA). The incidence, health service utiliza-
tion and household expenditure related to rotavirus gastroenteritis according to national income quin-
tiles were obtained from local data sources. Multiple birth cohorts were distributed into income quin-
tiles and followed from birth over the first five years of life in a multi-cohort, static model.  
Results: We found that the rich pay more out-of-pocket (OOP) than the poor, as the rich use more ex-
pensive private care. OOP payments among the poorest although small, are high as a proportion of 
household income. Rotavirus vaccination results in substantial reduction in rotavirus episodes and ex-
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penditure, and provides financial risk protection to all income groups. Poverty reduction benefits are 
concentrated amongst the poorest two income quintiles.  
Conclusion: We propose that universal vaccination complements health financing reforms in strength-
ening UHC. ECEA provides an important tool to understand the implications of vaccination for UHC, be-
yond traditional considerations of economic efficiency. 
 
Keywords: universal health coverage, poverty, catastrophic expenditure, equity, vaccines, mixed public-
private healthcare systems. 
 
Introduction 
The United Nations General Assembly has unanimously endorsed the goal of achieving Universal Health 
Coverage (UHC) (1). Towards achieving this goal, health systems are responsible for expanding the range 
of services that can be accessed, while ensuring equitable distribution of benefits and financial risk pro-
tection against the ‘catastrophic’ or impoverishing impact of healthcare payments (2, 3).  
The path to UHC is complex in middle-income countries with mixed public-private healthcare sys-
tems. Malaysia is widely credited as having achieved UHC through a public healthcare system that en-
sures access to subsidized healthcare for the whole population (4). However, perceptions of short-
comings in public healthcare, including long waits to access care and inadequate staff numbers, lead pa-
tients to seek care in the private sector (5). This exposes many to the financial risks of out-of-pocket 
(OOP) payments for private healthcare (6). Recent evidence suggests that OOP expenses for rotavirus 
gastroenteritis requiring hospitalization in Malaysia results in financially ‘catastrophic’ expenditure and 
even impoverishment, especially amongst the poor (7). Such OOP expenses are inconsistent with the 
stated aims of UHC, which is to deliver effective interventions while ensuring financial risk protection for 
all. 
Reliance on OOP healthcare payments, or direct payments for healthcare at the point of receipt of 
care, results in financial hardship among millions of people worldwide (8, 9). Unanticipated healthcare 
expenditure may not necessarily be large, but if above a critical fraction of household resources may dis-
rupt household living standards, and can be considered ‘catastrophic’ - exceeding a certain fraction of 
household income (10-13). Even small healthcare payments may push household income below the 
poverty line, resulting in or worsening poverty (12, 14, 15). 
The financial implications of OOP healthcare payments are different for the rich and the poor. The 
poor are likely to spend more of household income on basic necessities, like food, shelter and other es-
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sentials, thus are more vulnerable to unanticipated expenses. The rich have more resources and a better 
ability to smooth consumption (9, 16). Large OOP payments may deter the poor from seeking care, un-
derestimating the financial consequences of ill health (17). Other than the costs of actual treatment, the 
cost of seeking care including transportation and food, may adversely impact household welfare (18). 
Financial risk protection, an essential component in achieving UHC, can be defined as access to 
quality healthcare as needed without incurring financial hardship (19). Preventive measures such as vac-
cination may be complementary to reducing the cost of treatment as a means to achieve UHC, since 
they remove the risk of having to pay for illness-related care. Their universal nature is particularly attrac-
tive in mixed public-private healthcare systems where financial risk protection cannot be achieved simp-
ly by offering free-at-the-point-of-use access to public healthcare services. 
Rotavirus is an important determinant of childhood diarrhea (20). By age of five years, almost every 
child worldwide would have experienced an episode of rotavirus diarrhea (21). In high- and middle-
income countries, mortality due to rotavirus is small, but associated morbidity may impose a heavy fi-
nancial burden on families (22). The homogeneity of rotavirus incidence across high- and low-income 
countries, irrespective of standards of sanitation and hygiene, is testament to the high transmissibility of 
the virus (20, 23, 24). 
As improvement in water and sanitation does not directly prevent viral infection, rotavirus vaccines 
are the only effective preventive measure. Two rotavirus vaccines have been licensed and widely availa-
ble globally. These vaccines are safe, efficacious and effective (25-28) and are recommended by the 
World Health Organization (WHO) for inclusion into National Immunization Programs worldwide (24). 
Although widely regarded as cost-effective interventions (29-31), rotavirus vaccines are expensive and 
vaccine introduction has been slow for middle-income countries, like Malaysia, with low rotavirus mor-
tality (22, 32, 33).  
In this study, we use an extended cost-effectiveness analysis (ECEA) to evaluate the impact of rota-
virus vaccination in Malaysia. The ECEA explicitly estimates financial risk protection, considered essential 
by the WHO towards UHC (2). Also, the ECEA methods exhibit a vector of poverty reduction critical for 
Ministers of Finance, development agencies and funders, in considering investments in health. The 
global importance of poverty alleviation is exemplified with the Sustainable Development Goals, in 
which the first goal is a commitment to eradicate poverty in all its forms everywhere (34). These dimen-
sions provide additional information to better enable decision-makers to evaluate policy on the public 
finance of health programs (35).  
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Methods 
Overview 
The ECEA framework was used to evaluate public financing of universal rotavirus vaccination in Malaysia 
from the household’s perspective, across four dimensions (a) health benefits gained - hospitalizations 
and clinic visits averted, (b) household healthcare expenditure crowded out - direct medical and non-
medical costs averted, (c) financial risk protection afforded - prevention of financially catastrophic and 
impoverishing payments, and (d) equity - the distributional consequences of vaccination across national 
income quintiles. 
Rotavirus incidence, health service use, illness-related expenditure and other input parameters 
were obtained from local data sources. Age-stratified cohorts were distributed into national income 
quintiles and followed from birth over the first five years of life in the POLYMOD model. The POLYMOD 
model is a static, multi-cohort model designed by researchers at several European countries (36-38). The 
impact of monovalent Rotarix® (GlaxoSmithKline, Rixensart, Belgium) was considered in the base-case. 
We assume that a universal rotavirus vaccine in Malaysia, will follow the routine schedule for diph-
theria-tetanus-pertussis (DTP) vaccines and be administered at two and three months for Rotarix®. Ro-
tavirus vaccine coverage is based on the 2013 third dose DTP coverage of 97 percent in Malaysia (39).  
Malaysia had an under-five mortality rate of nine per 1,000 live births in 2013, and is categorized in 
the low mortality strata according to WHO Strategic Advisory Group of Experts on Immunisations (SAGE) 
definitions (40, 41). Vaccine efficacy was estimated for rotavirus vaccines in Malaysia, based on studies 
conducted in countries within the low mortality strata. This estimation is detailed in the appendix (Sup-
plementary text 1). 
The base year for analysis is 2013. An annual discount rate of three percent was used (42). Analysis 
was conducted using Microsoft Excel® Professional Plus 2013 and R version 3.2.0 (2015-04-16). Parame-
ters in the base-case are listed in Table 1. Presented next are the main data sources, a description of 
terms and methods used in the analysis.  
 
Data sources  
The National Health and Morbidity Survey 2011 (NHMS 2011), a nationwide health survey conducted by 
the Ministry of Health (MOH), Malaysia provided us with average OOP healthcare expenditure and utili-
zation patterns for inpatient and outpatient care, at public and private health facilities by national in-
come quintiles in Malaysia (43).  
A two-year, prospective rotavirus study conducted at two public hospitals in Malaysia collected in-
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formation on illness-related expenditure for all children under-five years admitted for acute diarrhea (7). 
As income groups from this 2010 hospital-based rotavirus study corresponds with the national income 
quintiles from the NHMS 2011, we obtained healthcare expenditure for rotavirus episodes treated at 
public hospitals by income quintiles from this study (7, 43). 
An estimation of the health and economic burden of rotavirus diarrhea in Malaysia has recently 
been published (44). This paper uses multiple data sources including national administrative data, na-
tional health surveys, annual reports, published and unpublished studies to estimate rotavirus deaths, 
hospitalizations, outpatient visits, and home-treated episodes, and the economic burden of rotavirus di-
arrhea to the healthcare provider and society. Please see the appendix for a summary of this estimation. 
(Supplementary text 1 to 3).  
 
Description of terms 
Rotavirus incidence refers to episodes of rotavirus diarrhea presenting to the healthcare system, requir-
ing either inpatient or outpatient care, at public or private facilities. As rotavirus diarrhea occurs in all 
children irrespective of socio-economic status (20, 24), episodes of rotavirus diarrhea were distributed 
evenly across income quintiles. Malaysia has a tax-based, public healthcare system which permits access 
to healthcare for all people regardless of income. However, use of public and private healthcare varies 
according to household income. Health service use by income quintile obtained from the NHMS 2011, 
allowed for the distribution of rotavirus episodes to public or private care in each income quintile (43). 
(Table 2) 
Illness-related expenditure incurred by households includes OOP direct medical costs on the receipt 
of care, like consultation and medication charges, and non-medical costs above normal consumption for 
transportation, diapers and food, during an illness episode. We obtained direct medical costs for public 
inpatient care from the 2010 hospital-based rotavirus study (7). The ratio of healthcare costs at private 
to public healthcare by income quintile from NHMS 2011 was multiplied to the public inpatient costs, to 
allow for the estimation of private inpatient costs. OOP direct medical costs for public and private out-
patient visits were obtained directly from the NHMS 2011 (43). Direct non-medical costs for public inpa-
tient care by income quintile were obtained from the 2010 hospital-based study (7). Direct non-medical 
costs for episodes requiring private inpatient care, and outpatient care at public and private settings, 
were recently estimated for Malaysia (44). These costs were distributed into income quintiles, using 
weighted averages of direct non-medical costs from the 2010 hospital-based study (Table 3). 
Catastrophic expenditure is defined here as illness-related expenditure exceeding 10% of monthly 
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household income. Illness-related expenditure exceeding the threshold of 10% of total household in-
come is considered to be at the expense of consumption of essential goods and services, adversely im-
pacting household living standards and thus financially catastrophic (13, 45). Although there is some de-
bate on the appropriate threshold for use as a marker of catastrophic expenditure, we use here a 
threshold of ten percent of monthly household income as previously employed by the World Bank (13). 
Analysis with catastrophic expenditure thresholds of 5, 10, 15 and 20% of household income have been 
included in the appendix (Supplementary text 4). While illness-related expenditure is usually defined as 
catastrophic when it exceeds a fraction of household income over a given period of a year, here ex-
penditure incurred is compared with monthly income (13). As rotavirus gastroenteritis is an acute ill-
ness, lasting no longer than a week and unlikely to be repeated, costs and income were not annualized 
in this analysis. (46). 
Impoverishment: Illness-related payments were considered impoverishing when households with 
monthly income above the poverty line fall below the 2009 Poverty Line Income for Malaysia (US$ 271 
in 2013 US$), after payment of expenses for rotavirus episodes (47).  
 
Analytical methods 
The distributions of OOP direct medical costs and household income were approximately log-normal. 
The mean and standard deviation of each income quintile were used to generate log-normal distribu-
tions of income. Mean of direct costs and standard deviation of OOP direct medical costs were used to 
generate log-normal distributions of direct costs by income quintile. Subsequently, the proportions of 
those incurring catastrophic expenditure or impoverishment in each income quintile were estimated. 
The estimation of standard deviation of OOP direct medical costs by income quintile is shown in the ap-
pendix (Supplementary text 2). 
To evaluate the impact of vaccination in reducing catastrophic and impoverishing payments, vaccine 
efficacy specific to inpatient and outpatient treated episodes was multiplied with the proportions of cat-
astrophic payments and impoverishment for each of these categories. 
 
Sensitivity analysis 
To test the robustness of our findings, we first pursued univariate sensitivity analysis, in which individual 
parameters were varied while others were fixed at base case values. These parameters were OOP direct 
costs, health utilization of public and private healthcare, and vaccine efficacy. Secondly, we conducted 
scenario analysis.  
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Alternate scenarios were considered to explore the uncertainty around vaccine impact estimates. 
These scenarios were vaccination with RotaTeq® (Merck & Co. Inc., West Point, PA, USA), and the addi-
tional benefits of herd protection. By means of scenario analysis the impact of vaccination on all illness-
related costs relevant to households was evaluated, including all direct and indirect costs. Detailed 
methods and results for the univariate sensitivity analysis and scenario analysis are provided in the ap-
pendix. (Supplementary text 7 and 8). 
 
Results 
General 
Although rotavirus episodes are distributed evenly across income quintiles, utilization of public and pri-
vate services vary by income. The rich use more private care than the poor, and the poor use more pub-
lic care. However, despite the availability of subsidized public care, the poorest still use private care, es-
pecially for outpatient treatment (Tables 1 and 2). 
We found that the richest spend more on rotavirus-related direct costs compared to all other in-
come groups especially the poorest (US$ 277 vs. US$ 24). (Figure 1). The richest are likely to incur higher 
healthcare expenditure due to utilization of more expensive private care (Tables 2 and 3).  
Prior to deducting healthcare expenditure, thirty-nine percent of the poorest quintile had monthly 
income below the national poverty line. Although the poor pay less than the rich in direct costs, the 
poorest pay almost as much as the richest as a proportion of monthly income (8% vs. 11%) (Figure 1). 
Direct costs paid OOP for rotavirus results in catastrophic expenditure among all income groups, 
and impoverishment among the poorest two quintiles. Surprisingly, 43% of the richest quintile spent 
more than 10% of household income on illness-related expenditure, although none were impoverished. 
Despite the high-frequency of catastrophic payments among the richest, the poorest were more vulner-
able to health shocks with sixteen percent experiencing catastrophic payments and 7% impoverished 
due to rotavirus-related expenditure (Table 4). 
 
Base-case 
We found that rotavirus vaccination resulted in substantial reduction in rotavirus episodes and expendi-
ture across all income groups. Annually, rotavirus vaccination resulted in savings of almost US$ 6 million 
to households seeking care for rotavirus episodes. These benefits were evenly distributed across income 
quintiles (Table 4). In terms of financial risk protection, vaccination averts catastrophic expenditure 
among all income groups. However, poverty reduction benefits were concentrated among the poorest 
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two quintiles.  
 
Sensitivity analysis 
We found that changes in direct costs have proportionate impact on households, in terms of cata-
strophic and impoverishing events. When healthcare usage patterns were assumed to be equal for all 
income groups, the household impact of healthcare payments in terms of catastrophic and impoverish-
ing events was blunted amongst the richest income quintile. Even at a lower estimation of vaccine effi-
cacy, Rotarix® is effective in reducing about 67-70% of rotavirus episodes, direct costs, catastrophic and 
impoverishing events in all income quintiles. 
Our findings suggest that both commercially available vaccines have similar impact and distribu-
tional implications. Herd protection provides additional benefits particularly to those with the least ac-
cess to healthcare services. Results of the univariate sensitivity analysis and scenario analysis are de-
tailed in the appendix (Supplementary text 7 and 8). 
 
Discussion 
We found that all households regardless of income, experienced some degree of catastrophic payments 
due to illness-related expenditure for rotavirus care. However, only households in the two poorest quin-
tiles were impoverished as a result of healthcare payments. Universal rotavirus vaccination helps allevi-
ate catastrophic expenses among all income quintiles, and prevents impoverishment among the poorest 
two quintiles. 
Hence universal rotavirus vaccination, free at the point of use, can be considered a pro-poor policy 
that reduces health and social inequalities. However, these benefits are not exclusive to the poor. Our 
results show that people in all income quintiles benefit in terms of financial risk protection. Preventive 
measures such as rotavirus vaccination are able to avert both the cost to households of actual treat-
ment, which are highly subsidized in the public sector in the Malaysian context, but also the cost of 
seeking care.  
These findings suggest that universal, publicly-financed rotavirus vaccination, and potentially other 
childhood vaccines administered to all, may be best regarded as common goods to be made freely avail-
able to everyone, rather than a means-tested benefits program targeted at the poor only. A publicly-
financed, universal vaccine policy can be seen to protect all income groups. Hence it is most likely to 
achieve political support for cross-subsidization from the rich to the poor. This has implications beyond 
Malaysia to other middle-income countries considering between alternative strategies towards UHC.  
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Demonstrated here are the social values of fairness and distributional justice promoted by universal 
vaccination, by allowing access to health benefits and financial risk protection for all. Public financing of 
programs designed for promoting equity benefits, for example a basic package of essential care includ-
ing childhood vaccines, may enhance social solidarity. 
Healthcare in many middle-income countries is often delivered by mixed health systems. In this en-
vironment, publicly-financed government healthcare delivery coexists with privately-financed market 
delivery, in which OOP payments dominate as a means of financing (48). Reliance on OOP payments 
may have detrimental consequences on household welfare, exacerbating poverty and inequities in both 
health outcomes and healthcare payments.  
In Malaysia, the availability of a parallel private health system exposes many to the financial risk of 
direct payments for healthcare (49). Household OOP expenditure in Malaysia is the largest source of fi-
nancing in the private sector amounting to 79 percent of spending in this sector, or 37 percent of total 
health expenditure in 2012 (50). Our findings, that the rich opt-out of public care in Malaysia, has simi-
larities with Thailand, where the better-off are at risk of catastrophic expenditure despite universal cov-
erage (51). However, our findings show that the poor also rely on private healthcare, despite the heavy 
financial burden this often causes. 
Health financing strategies towards achieving UHC, either general taxation or national insurance-
based, provide protection against OOP healthcare payments for accessing public healthcare, but not 
against non-medical spending associated with illness nor against user fees for private healthcare. We 
propose universal vaccination as a social protection policy against medical and non-medical spending, 
associated with ill health.  
There are several limitations to this study. Firstly, there is no universally accepted definition of what 
is considered an ‘excessive’ financial loss following illness, against which governments should protect 
their populations. Because of this, we used two alternative but widely accepted measures. The first de-
fines healthcare expenditure as catastrophic if it exceeds a defined threshold of household income over 
a specified duration of time. This acknowledges that households of any income can be badly hit by 
healthcare expenditure even if they are not forced into poverty. The second defines healthcare expendi-
ture as impoverishing when the post-expenditure household income falls below a fixed threshold, either 
international or national. In both cases, the use of threshold-based metrics for measuring financial risk 
protection, has inherent methodological issues. 
These metrics may underestimate financial hardship, as the poor may be deterred from using 
healthcare as a result of high user fees. Also threshold-based metrics fail to consider coping mechanisms 
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like savings, borrowing or selling of assets (12, 19, 52). Despite these acknowledged limitations, thresh-
old-based metrics are well established and widely used by policymakers, thus chosen for this study. 
Measures of financial risk protection are usually conducted for research on health systems financ-
ing. In health systems research, definitions of catastrophic expenditure usually compare all healthcare 
expenses against all household resources, over a period of a year. This current study examines the effect 
of illness-related expenditure for rotavirus on monthly income, and the benefits of universal vaccination 
in alleviating this burden. This differs from health systems research in two ways.  
Firstly, the numerator used in this study are expenses specific for rotavirus gastroenteritis and not 
all healthcare expenses, generally used in health systems research. Secondly, we consider illness-related 
expenditure to be catastrophic when it exceeds the defined threshold of household income over a dura-
tion of a month. As rotavirus gastroenteritis is an acute illness (46), we compare illness-related expenses 
with monthly income. Expenses over a short term have a different impact on household welfare com-
pared to expenses over a longer period, as some households are better able to use current income, sav-
ings and established family or social networks to cope. Nevertheless, an unexpected, large expense may 
adversely impact poor households with less resources to cope with (18). 
We chose not to consider the impact of wage loss on household income in the base case. While in-
direct costs are important when considering the impact of illness on the national economy, when a 
household perspective is taken, these costs are more important in low-income countries with a large in-
formal sector, where household income is dependent on daily wage (18). In most high- and middle-
income countries, much of the labor force is part of the formal market, and as such absenteeism for a 
short illness may not impact household income. In the Malaysian context, lost wages may only impact 
the poorest, as they are more likely to be employed in the informal or casual workforce. Hence as seen 
in the scenario analysis, the distributional impact of vaccination may be even more pro-poor.  
The economic costs of diarrheal deaths were not considered here as Malaysia has low rotavirus 
mortality, with 15 rotavirus deaths among children younger than five years estimated for 2008 (22). 
While, rotavirus vaccination would substantially reduce rotavirus mortality in Malaysia, estimation of 
the productivity gain of mortality averted is likely to be more important in low-income countries, with 
higher rotavirus mortality. Also, we do not consider expenditure for informal care as this is not relevant 
to the setting. In Malaysia, less than three percent of children under-five years with acute diarrhea seek 
care at non-medical facilities, like traditional healers or Chinese medicine shops (53). 
Vaccines have long been regarded as cost-effective interventions towards improving population 
health (54). However, newer vaccines such as rotavirus are more expensive than traditional vaccines, 
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particularly in middle-income countries ineligible for lower prices offered by Gavi, the Vaccine Alliance 
(32). Some economists have suggested that the economic case for vaccination has been understated be-
cause traditional evaluations of vaccines focus on health gains and savings to the health system, under-
estimating the broader benefits of vaccination to households and the wider economy (55-57).  
From a household perspective, poverty reduction and financial risk protection could be viewed as 
important aims of healthcare systems that would strengthen the case for vaccine introduction. Middle-
income countries like Indonesia, Sri Lanka, Viet Nam and others (58) that have yet to introduce rotavirus 
vaccines could potentially benefit from the broader social and economic impact of rotavirus vaccination. 
The tools employed here are easily adaptable to other settings with different immunization programs 
and health systems, to measure the essential role of vaccines towards UHC. 
 
Conclusions 
A key objective of UHC is to reduce social disparities in healthcare spending. We propose that well-
designed universal vaccination programs complement health systems financing reforms in attaining and 
strengthening UHC. ECEA provides an important tool to understand the implications of vaccination for 
UHC beyond traditional considerations of economic efficiency. Our findings may hold lessons for other 
settings, particularly emerging economies with mixed public-private healthcare systems. 
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